03:16 PM EST - Medicenna Therapeutics Corp. : Announced that following the presentation of early results at the Congress for Neurosurgeons (Oct 9-11), additional clinical data from the on-going Phase 2b clinical trial of MDNA55 were presented at the 22nd Annual Meeting of the Society of Neuro-Oncology being held in San Francisco. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.01 at $2.56.
